【Can-Fite BioPharma-Product CF102】Can-Fite BioPharma Enters Into Collaboration Agreement to Explore Namodenoson’s Anti-NASH Effect With Icahn School of Medicine at Mount Sinai in NYC

Partner News

10th December 2018 – Can-Fite
Biopharma Limited issued an announcement, which is summarized as follows: 

Can-Fite BioPharma Limited announced a collaborative research agreement
with the Icahn School of Medicine at Mount Sinai in New York City. The
agreement will support research directed by Scott Friedman, M.D., Dean for
Therapeutic Discovery and Chief of the Division of Liver Diseases at the Icahn
School of Medicine. The research is aimed at transcriptomic and molecular
analyses to further explore the mechanisms of action of Namodenoson (CF102) in
human hepatic stellate cells in order to clarify its effect on fibrogenesis
that occurs in non-alcoholic steatohepatitis (NASH).

The original website link: